Betalin Therapeutics is a privately-held company bio-technology company developing a cell-therapy solution for all insulin dependent diabetics: Engineered Micro Pancreas (EMP). The EMP is a coalescence of harvested pancreatic islets and an organ-derived micro-scaffold-matrix (MOM). In recent years, islet transplantation has been researched as a treatment for T1DM; this treatment is known as the Edmonton Protocol. The Edmonton Protocol, restores glyco-metabolic control for short periods of time and slows the progression of diabetic complications. These functions are achieved by transplanting naked, insulin producing islets into the liver. But unfortunately, once the naked islets are transplanted, 80% of them die within 24 hours. So, by imbedding islets into an MOM before transplantation, the islets' longevity increases dramatically within the confines of the scaffold, and creates the EMP which is then implanted into the patient. Our approach is revolutionary and has the potential to radically improve the lives of 170 million people worldwide. The EMP treatment was successful when tested on insulin dependent mice. We plan to advance to clinical trials in 2020.